MOMC-4. Proteogenomic and metabolomic characterization of glioblastoma. (5th July 2021)

• Record Type: Journal Article
• Authors: Wang, Liang-Bo; Karpova, Alla; Gritsenko, Marina; Kyle, Jennifer; Cao, Song; Li, Yize; Rodland, Karin; Liu, Tao; Ding, Li
• Is Part Of: Neuro-oncology advances. Volume 3(2021)Supplement 2
• Page Start: ii4
• Page End: ii4
• Publication Date: 2021-07-05
• Subjects: 616.99481
• DOI: 10.1093/noajnl/vdab070.014
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Glioblastoma (GBM) is the most aggressive nervous system cancer, with median survival under 2 years. Understanding its molecular pathogenesis is crucial for improving diagnosis and treatment. We performed an integrated analysis of genomic, proteomic, post-translational modification and metabolomic data on 99 treatment-naive GBMs. We identified key phosphorylation events (e.g., phosphorylated PTPN11 and PLCG1) as potential switches mediating oncogenic pathway activation as well as potential targets for EGFR-, TP53- and RB1-altered tumors. We detected immune subtypes, driven by the presence of distinct immune cell populations using bulk omics, validated by single nulcei RNA sequencing (snRNA-seq), and they were correlated with specific expression and histone acetylation patterns. Acetylation of histone H2B in classical-like and immune-low GBM was driven largely by BRDs, CREBBP, and EP300. Integrated metabolomic and proteomic data identified specific lipid distributions across subtypes and distinct global metabolic changes in IDH mutated tumors. This work highlights biological relationships which could potentially aid GBM patient stratifications for more effective treatments.